Table 2.
Posttransplantation clinical events and transplant outcomes of the study cohort
| Parameter | All (n = 54) |
|---|---|
| Immunogenic posttransplantation complications | |
| aGVHD, n (%)∗ | 40 (74.1) |
| >1 episode within 1 year after HSCT, n (%) | 8 (14.8) |
| Severe aGVHD, grade ≥3, n (%) | 6 (11.1) |
| cGVHD, n (%) | 13 (24.1) |
| >1 episode within 1 year after HSCT, n (%) | 2 (3.7) |
| Moderate-to-severe cGVHD, n (%) | 9 (16.7) |
| Infectious posttransplantation complications | |
| Chronic viral infection, n (%) | |
| CMV | 13 (24) |
| EBV | 11 (20.4) |
| HHV-6 | 6 (11.1) |
| HHV-8 | 1 (1.9) |
| HSV | 3 (5.6) |
| BKV | 5 (9.3) |
| Respiratory viral infections, n (%) | |
| Influenza | 5 (9.3) |
| SARS-CoV-2 | 16 (29.6) |
| RSV | 4 (7.4) |
| Rhinovirus | 5 (9.3) |
| Bacterial infections, n (%) | 26 (48.2) |
| Transplantation outcomes, n (%) | |
| Disease relapse | 11 (20.4) |
| Overall survival at 1 year after HSCT | 50 (92.6) |
aGVHD, acute graft-versus-host disease; BKV, polyomavirus BK; cGVHD, chronic graft-versus-host disease; EBV, Epstein-Barr virus; HHV-6, human herpesvirus 6; HHV-8, human herpesvirus 8; HSV, herpes simplex virus; RSV, respiratory syncytial virus.
∗
Classification of aGVHD grading according to the National Institutes of Health criteria in which aGVHD can occur beyond 3 months based on clinical manifestations.